Markets
Palantir CEO Alex Karp PLTR insane valuation
(Kevin Dietsch/Getty Images)

Palantir slips under 50-day moving average, amid momo reversal

What goes up, doesn’t always keep going up.

Matt Phillips
9/5/25 12:11PM

Palantir shares are getting bruised by the momentum-driven sell-off washing over the stock market Friday, with its slide pushing the price well below the 50-day moving average.

In fact, Palantir is down more than 18% from the high levels it hit in early August, a drop that earlier this week forced it to cede its crown as the top-performing issue in the S&P 500 this year.

The slump Friday comes amid another down day for so-called momentum stocks. (Momentum is one of the “factors” adherents of factor investing try to manipulate to optimize their portfolios. It essentially is a catchall for stocks that have been going up for a while.)

Palantir is one of them. The company has been one of the more remarkable investments in recent memory, rising roughly 2000% over the last three years, and creating about $340 billion in stock market wealth—with the vast majority of those gains generated over the last 12 months.

Why has it done so well?

Well, the provider of national defense data services and AI software for corporate clients, is clearly a great company delivering outstanding results. (See, our coverage of its most recent earnings results for example.)

In fact, its rather brash executive suite continuously touts the fact that its growth and free cash flow profitability is roughly double the so-called “Rule of 40” that that software-as-a-service company’s target as the ideal mix of growth and profit. (Jonathan Weil over at the Wall Street Journal has good explainer on the Rule of 40 here.)

But one way to interpret the recent wobble in the company’s share price is that the market is starting to question how long such high levels of growth and profitability can persist.

After all, standard economic theory suggests that high growth and high profitability act almost as the chum of capitalism, attracting the attention of would-be predatory competitors from far and wide.

How quickly that competition shows up depends on how high the barriers to entry are for others.

But as today’s big news from Broadcom suggests, even dominant players like Nvidia ultimately face competitive threats.

Surely, some investors are might consider whether companies like Palantir will face chippier competition in the future. As it turns out, they are. Reflecting such concerns, William Blair analysts wrote in a note on Friday:

While Palantir continues to experience major momentum, some investors are concerned about how the competitive landscape evolves five years from now with OpenAI and peers rapidly raising capital, poaching talent, emulating the forward deployed engineer model, and aggressively pursuing the enterprise and defense end markets.

Other big SaaS companies have also been elbowing into Palantir’s lane. For instance, Salesforce CEO Marc Benioff recently talked up his compay’s ability to snatch an Army contract from Palantir telling CNBC,

“We had a tremendous success against Palantir, because, by the way, our prices are just so much lower,” Benioff said. “We’re offering a very competitive product as a much lower cost.”

That doesn’t mean Palantir is poised to have its lunch eaten by competitors any time soon. But even a modest reduction in a company’s growth and profit trajectory can have an outsized impact on a stock like Palantir, which, even after the recent sell-off, remains insanely richly valued.

Nor does it mean that Palantir’s share price is doomed to fall from here. We saw a very similar sell-off in momentum shares set in back in February that stretch through April, before retail traders rushed in to buy the dip, and realize strong gains in the following months as the market recovered.

But, it stands to reason that, if the risks of competition are starting to creep into the minds of investors, that could be an important — and perhaps overdue — shift in the psychology of investors away from gauzy fantasies about a highly profitable AI future inevitably dominated by today’s market leaders like Nvidia and Palantir.

And if investors are starting to think about pesky considerations like competition, it might — might! — complicate the knee-jerk, buy-the-dip momentum trading dynamic that’s been so important to the market’s resilience over the last year.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

markets

Momentum stocks reverse, weighing on US markets

Momentum stocks dragged the market lower Friday, with stocks like Palantir Technologies, SoundHound AI, Rocket Lab, Robinhood Markets, and GE Vernova continuing a recent slide.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company.)

The iShares MSCI USA Momentum Factor ETF opened 1% higher and built on those gains before reversing hard early in the session to trade 1% lower as of 11 a.m. ET.

If it closes at these levels, this fund that holds US stocks with the best risk-adjusted trailing returns will have completed a so-called “bearish engulfing candle pattern.” As the name suggests is, this is considered to be a negative technical signal that occurs when, the day after a security rises, it ends up opening above the previous day’s closing price and closes below the previous day’s opening price.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.